ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Media

12-Nov-2020

PharmaVoice, “a resource for life-sciences executives and other healthcare-service related professionals” posted the following News Release; Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

Click here to read more

10-Nov-2020

BiotechDispatch, a site dedicated to breaking news and commentary on the Australian biotechnology and life sciences sector reported

9-Oct-2020

Pharmaceutical Business Review wrote," As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda, in the company's Phase 1 NOXCOVID-1 study.

Click here to read more

8-Oct-2020

PharmaVOICE.com  A US industry digital news website said," NOXCOVID-1 is looking at treating those COVID-19 patients hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care and mechanical ventilation".

Click here to read more

8-Oct-2020

Bloomberg reported on Noxopharm's October 2, 2020 ASX announcement Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

Click here to read more

8-Oct-2020

BioWorld, in its In The Clinic section, reported on Noxopharm's NOXCOVID trial first COVID patient's treatment; "Treated first patient in Noxcovid-1 study enrolling subjects hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care and mechanical ventilation".

Click here to read more

8-Oct-2020

BioSpace, a US Life Sciences industry digital hub reported," Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

Click here to read more

21-Aug-2020

Global biotech news service, BioWorld, in its Other News To Note, covered Noxopharm's reporting (11 Aug 2020) that, " Independent research published in European Urology Oncology showed the combination of 177Lu-PSMA-617 radioligand therapy and Veyonda (idronoxil), its sphingosine-1-phosphate inhibitor, was safe and effective, with median overall survival (OS) of 17.1 months in late-stage prostate cancer patients who exhausted standard treatment options. Median OS in a study conducted in a comparable population who received standard chemotherapy was 4.5 months." 

Click here to read more.

19-Aug-2020

US Life Science website, Clinical Research News, said Noxopharm had announced new research showing Veyonda® cancer survival rates in a peer-reviewed publication, European Urology Oncology,  the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer.

Click here to read more.